Baird Barbara
Associate Professor, Department of Women's Studies, Faculty of Social & Behavioural Sciences, Flinders University, Adelaide SA, Australia.
Reprod Health Matters. 2015 Nov;23(46):169-76. doi: 10.1016/j.rhm.2015.10.002. Epub 2015 Dec 4.
Surgical abortion has been provided liberally in Australia since the early 1970s, mainly in privately owned specialist clinics. The introduction of medical abortion, however, was deliberately obstructed and consequently significantly delayed when compared to similar countries. Mifepristone was approved for commercial import only in 2012 and listed as a government subsidised medicine in 2013. Despite optimism from those who seek to improve women's access to abortion, the increased availability of medical abortion has not yet addressed the disadvantage experienced by poor and non-metropolitan women. After telling the story of medical abortion in Australia, this paper considers the context through which it has become available since 2013. It argues that the integration of medical abortion into primary health care, which would locate abortion provision in new settings and expand women's access, has been constrained by the stigma attached to abortion, overly cautious institutionalised frameworks, and the lack of public health responsibility for abortion services. The paper draws on documentary sources and oral history interviews conducted in 2013 and 2015.
自20世纪70年代初以来，澳大利亚一直广泛提供手术流产服务，主要在私立专科诊所进行。然而，与其他类似国家相比，药物流产的引入遭到蓄意阻挠，因此被大幅推迟。米非司酮直到2012年才被批准商业进口，并于2013年被列为政府补贴药物。尽管那些致力于改善妇女堕胎途径的人抱有乐观态度，但药物流产可及性的提高尚未解决贫困和非大城市地区妇女所面临的不利处境。在讲述了澳大利亚药物流产的情况后，本文探讨了自2013年以来其得以应用的背景。文章认为，将药物流产纳入初级卫生保健，即在新环境中提供堕胎服务并扩大妇女的可及性，受到堕胎污名、过于谨慎的制度化框架以及对堕胎服务缺乏公共卫生责任的限制。本文借鉴了2013年和2015年的文献资料及口述历史访谈。
